Background: Screening and treatment of latent TB infection (LTBI) and TB disease could reduce diabetes mellitus (DM)-associated TB. We aimed to describe the prevalence of LTBI and pulmonary TB among patients with DM in a TB-endemic setting.
Introduction
Globally, the prevalence of diabetes mellitus (DM) in adults was estimated to be 8% of the population (400 million people) in 2015, and to increase by 50% by 2040. 1 Patients with DM are three times more likely to develop TB, [2] [3] [4] and have poorer TB treatment outcomes. 5, 6 Low-resource countries have an increasing prevalence of DM and an ongoing high incidence of TB. 1, 7, 8 Indonesia is both a high DM (6.2%) 1 and high TB prevalence country (647 per 100 000). 9 In 2010, approximately 9.5% of all TB cases in Indonesia were thought to be attributable to DM, estimated to increase to 14% by 2030. 7 While the lower immunity in patients with DM and factors related to hyperglycaemia are thought to increase susceptibility to TB disease, 2, 8, 10, 11 little is known about the interaction of DM with latent TB infection (LTBI). In a recently published systematic review and meta-analysis of studies, mostly in high risk populations in developed countries, DM was associated with a small but statistically significant increase in risk for LTBI. 12 In studies of patients with DM in Singapore (n=220) 13 and Mexico (n=605) 14 LTBI prevalence in patients with DM was 29% and 39%, respectively.
The Indonesian National TB Programme recommends screening and treatment for TB disease in family members of a TB positive patient, and screening and treatment for LTBI for HIV patients and children under 5 years of age, but this is rarely done. There is currently no universal consensus on recommendations for routine screening and treatment for TB disease or LTBI in patients with DM 15 and there are limited data to inform recommendations on the prevalence of LTBI in patients with DM, their rate of progression to active TB and the benefits of preventive therapy. We therefore conducted a cross-sectional study in patients with DM in Indonesia, and compared them to a matched control group of household contacts of patients with TB, to gain insight into the prevalence of LTBI and pulmonary TB disease, and to identify any associated risk factors for LTBI.
Methods Study setting, participants and eligibility criteria
The study is part of the TANDEM research program 16 conducted in Bandung City (population approx. 2.5 million), West Java, Indonesia. Eligible patients aged 18 and over with known DM were recruited (February 2014 (February -2015 A control group comprised non-DM household contacts of patients with TB who were recruited in a separate study in Bandung from February 2014 to February 2016. This group was selected for comparison as they are also known to be at high risk of developing TB disease, but most likely due to high rates of LTBI from intense exposure to a patient with TB rather than through specific immune deficit. Therefore, we expected patients with DM to have a lower prevalence of LTBI than contacts with TB. The included contacts were aged 25-54 years old, living in the same household as an individual with a sputum smear positive result, and had a valid interferon gamma release assay (IGRA) test result. 
Interview, clinical and laboratory examination with patients with DM
Study doctors conducted an interview and clinical examination with each patient with DM, covering socio-demographic characteristics and health behaviours. Diabetic history included the duration of disease, medication and diabetic complications. Self-reported data were cross-checked with medical records. Anthropometric data (weight and height) were measured for calculation of body mass index (BMI) using calibrated digital scales. Blood taken for glycated haemoglobin (HbA1c) was sent to a certified laboratory for measurement.
Patients were asked whether they had a history of TB or were currently taking TB medication. Enquiry about TB symptoms included cough, sputum production, fever, dyspnoea, weight loss and chest discomfort. All patients underwent a chest x-ray that was read by a radiologist independent of the study. Those who had a chest x-ray result suggestive of pulmonary TB and/or symptoms of cough for two or more weeks were asked to give two sputum samples for acid-fast bacilli smear and Mycobacterium tuberculosis culture. Xpert MTB/RIF positive was also done on those suspected to have drug-resistant TB.
Patients with and without a past history of TB were classified into four categories: active TB: on anti-TB medication, or M. tuberculosis culture or Xpert MTB/RIF positive; probable TB: TB symptoms, chest x-ray suggestive of TB and smear positive but culture negative; possible TB: TB symptoms and/or chest x-ray suggestive of possible TB, but smear and culture negative; and no TB: no evidence of TB on symptom review or investigations.
Possible TB patients were followed up, on average 10 months after recruitment, with a repeat examination; anyone with an M. tuberculosis culture or Xpert MTB/RIF positive result was reclassified as active TB.
All patients underwent screening for LTBI by the QuantiFERON-TB Gold In-Tube (QFT) Interferon Gamma Release Assay (IGRA). 17 Control group participants were screened for LTBI in the same laboratory, using the same QuantiFERON supplies and collection techniques as for the patients with DM.
No routine testing for HIV was done, noting that the HIV prevalence in adults aged 15-49 in Indonesia 0.5%. 18 
Matching patients with DM and control patients
Patients with DM were stratified by sex, and frequency matched one-to-one to control group participants, in three 10-year age brackets (25-34, 35-44, 45-54) to compare the prevalence of active TB and TB history in the two groups. Where more controls were available in any one bracket, participants were randomly selected using computer-generated list of random numbers in Excel, version 15.32 (Microsoft Corp., Redmond, WA, USA) to provide the exact number required. The same process-including only those considered 'TB-disease free'-was repeated to compare LTBI prevalence (see Supplementary data).
Statistical analysis
A binomial exact test was used to generate the 95% confidence intervals for prevalence rates. The one-way analysis of variance and Student's t-test were used to compare mean values. Characteristics, identified from the literature to be associated with LTBI or TB disease, were analysed using logistic regression in a univariable analysis to generate odds ratios. To determine characteristics associated with IGRA positivity, a multivariable logistic regression model was then constructed to adjust for age, sex and any other variable that reached a p-value of less than 0.20 in the univariable analysis. Mann-Whitney and Kruskal-Wallis tests were used to test associations between quantitative IGRA and indicators of severity of diabetes. Linear regression was used to estimate the correlation coefficient between laboratory HbA1c and TB antigen-induced interferon-gamma (IU/mL). To compare the prevalence of LTBI and active TB between the DM patients and control group, a two-sample test of proportions was used. Study R. C. Koesoemadinata et al. data were managed using REDCap electronic data capture tools. 19 Statistical analyses were performed using STATA Version 12.1. 20 
Results

Study participants
Of 682 patients with DM seen, 654 were eligible and consented to participate. Three patients did not have an IGRA test taken, leaving 651 (95.5%) for analysis. Almost all patients had Type 2 DM (644, 98.9%), the majority were aged over 50 years (554, 85.1%) and about half (338, 51.9%) were on metformin either alone or in combination with another oral anti-DM medication (Table 1) . Those recruited through CHCs (317, 48.7%) were more likely to be female (231, 72.9% vs 202, 60.5%; p=0.001) and were slightly older (mean age 60 years vs 58 years; p=0.005) than those recruited at the hospital endocrine clinic. A total of 414 TB case contacts aged 25-54 were available for matching.
Prevalence of LTBI
The prevalence of LTBI in patients with DM who were 'TB-disease free' (excluding indeterminate results) was 38.9% (206/530; 95% CI 34.7-43.2). None of these patients had any evidence of TB on symptom review, chest x-ray, smear or culture.
The comparison of 'TB-disease free' patients with DM and the control group for LTBI prevalence included 140 individuals in each group. The proportion IGRA positive was 38.6% (54/140; 95% CI 30.5-46.6) in the DM group compared to 68.6% (96/ 140; 95% CI 60.9-72.3) in the control group (p<0.001).
Active TB
Of the patients with DM who were defined as 'not TB-disease free', 24 had active TB, 40 were possible TB (based on their chest x-ray result) and 35 had a history of TB (Figure 1 ). There were no patients with probable TB. Of the 24 patients categorised as active TB, 12 were already on TB treatment (smear positive [n=7], extra-pulmonary TB [n=2], smear negative but chest x-ray positive [n=1], no other diagnostic information available [n=2]). Ten further patients were found through TB screening: seven presented with symptoms, three with suggestive chest x-ray lesions, and all had a positive culture or Xpert MTB/ RIF result. Two patients were originally classified as 'possible' TB but were diagnosed with active TB after follow-up.
The comparison of patients with DM with the control group for active TB prevalence included 164 individuals in each group. The proportion with active TB in the DM group was 4.9% (8/164; 95% CI 1.6-8.2) compared to 1.2% (2/164; 95% CI -0.5 to 2.9) in the control group (p=0.054). The eight DM active TB cases and the two household contacts all had a positive culture. The proportion in both groups with a history of TB was 5.5% (9/164; 95% CI 2.0-9.0) compared to 6.1% (10/164; 95% CI 2.4-9.8), respectively.
Proportion IGRA positive by TB disease category in patients with DM
The proportion IGRA positive was highest in patients with DM with active TB decreasing across the three diagnostic categories 
Risk factors for LTBI in 'TB disease free' patients with DM
There were no significant associations between sex or age, and IGRA positivity. Patients with DM in a household with five or more people, had a significantly increased risk of being IGRA positive compared with those in a household with less than five people (OR 1.69; 95% CI 1.18-2.42) ( Table 2 ). This remained significant after adjustment for age, sex, and HbA1c (AOR 1.71; 95% CI 1.19-2.45). No significant differences were observed for any other socio-demographic characteristics. Patients with higher HbA1c, longer duration of DM, and complications of DM appeared to be more likely to be IGRA positive, while patients on DM medication had a reduced risk of being IGRA positive, but none of these results reached statistical significance ( Table 2 ). Analysis of the 14 patients who reported they had received treatment for renal failure (38.5% IGRA positive) also showed no significant result (OR 0.98; 95% CI 0.31-3.03).
Quantitative and indeterminate IGRA results in patients with DM
The TB antigen-induced interferon gamma production did not vary significantly across any of the four indicators of DM severity (Table 3 and Figure 3 ).
All indeterminate results in patients with DM were due to a low mitogen result. The overall proportion of indeterminate results was 4.9% (32/651; 95% CI 3.4-6.9), and 4.0% (22/552; 95% CI 2.0-5.9) in 'TB-disease free' patients. The characteristics of 'TB-disease free' patients with indeterminate results are shown in Table 2 . There was a significantly increased risk of having an indeterminate result for those who had an HbA1c ≥10% compared to those with an HbA1c <10% (OR 3.22; 95% CI 1.36-7.61). There were no significant findings with respect to other characteristics. The proportion of indeterminate results in the age and sex-matched groups was 3.6% (95% CI 1.2-8.1) in the DM group and 1.4% (95% CI 0.2-5.0) in the control group.
Discussion
The prevalence of LTBI was 38.9% (95% CI 34.7-43.2) in our study population of patients with DM. In the age-and sexmatched comparison, the prevalence in patients with DM (38.6%; 95% CI 30.5-46.6) was 30% lower than contacts of persons with TB (68.6%; 95% CI 60.9-72.3), while the prevalence of active pulmonary TB was higher in patients with DM (4.9% vs 1.2%).
Our overall LTBI prevalence estimate was lower than that reported in a similar DM population in Mexico (51%), 14 but higher than in Singapore (29%). 13 Both these studies, however, used TST for LTBI diagnosis and the Mexican study used a ≥5 mm cut-off for positivity; when using the recommended ≥10 mm cut-off (the same as in Indonesia) the prevalence was 39% -similar to our study. No population LTBI estimates are available to provide a context for these studies but in one large population-based study using IGRA in China (n=21 022) LTBI Transactions of the Royal Society of Tropical Medicine and Hygiene rates were between 13 and 20%. 21 Also using IGRA, an American study among a refugee population reported a LTBI prevalence of 43% in those with DM (n=54) and 39% in those with pre-DM (n=235), both of which were higher than the 26% in refugees without DM. 22 The DM refugee sample was small (n=54) and they were from a diverse range of countries with different underlying TB prevalence; therefore it is difficult to compare with our study. In a recent meta-analysis, the authors estimated that if the prevalence of LTBI is 30% in the non-DM population, the expected prevalence in the DM population would be 33.6%. 12 The lower LTBI prevalence in our matched patients with DM, compared to those in the control group, is not surprising given the control group was from households of known TB positive patients. 23 Other possible control groups are non-DM patients recruited from clinics, or individuals in the community. The selection of controls from either source, however, would need to be carefully done to ensure a robust comparison. A comparison with case contacts provides insight into the relative benefits of preventive therapy. A lower prevalence of LTBI and higher prevalence of TB disease suggests that patients with DM would benefit even more from preventive therapy than case contacts.
The prevalence of active TB in our study of patients with DM was 3.7% (95% CI 2.2-5.2) and 6.1% (95% CI 4.3-7.9) were categorized as possible TB. There was a higher prevalence of active TB in the matched DM group (4.9%) than the control group (1.2%), although this difference was of borderline significance (p=0.054) and the proportion with a history of TB was similar in both groups (5.5% vs 6.1%). Given the higher prevalence of active TB in the DM group, despite lower LTBI prevalence, the increased susceptibility to TB in patients with DM is ACR: albumin to creatinine ratio; BCG: Bacillus Calmette-Guerin; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate.
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unlikely to be primarily driven by relatively increased LTBI rates and patients with DM are similar to HIV patients in this regard. [24] [25] [26] A relatively high proportion of patients with DM with 'possible TB' had a past history of TB, in keeping with the high likelihood that cured TB patients have residual persistent changes on their x-rays such as that caused by fibrosis. While the IGRA was not used as a screening test to guide TB investigations in this study, we note that the one patient with active TB with a negative IGRA presented with a productive cough of more than 3 weeks, mandating sputum testing regardless of any x-ray result. Each of the three patients with active TB with indeterminate IGRA results were already on anti-TB medication at the time of recruitment. All of the patients in our study had a chest x-ray. However, if the chest x-ray had been restricted to only those with a positive IGRA, no TB cases would have been missed, but 349 x-rays avoided. A formal feasibility and cost-benefit analysis would be needed to show whether IGRA is preferred over x-ray for initial screening. Furthermore, it would be useful to conduct a formal comparison with TST.
In our study, the only significantly associated risk factor for LTBI in patients with DM was being in a household with a greater number of household members. Data were not collected on whether household members included someone with current or past history of TB. However, household crowding is a recognized risk factor for TB. 27, 28 The lack of significant findings with any of the other DM-specific characteristics such as use of DM medication or level of HbA1c, which have been reported to be associated with both active TB 3,5,29 and LTBI 13,14 is notable. In Singapore, the use of metformin was negatively associated with LTBI in a multivariate model, 13 yet no such association was seen in our study. For HbA1c, the odds ratios for patients with an HbA1c between 7.0 and 9.9% and ≥10% were both increased but neither of these results were significant. A similar lack of any statistically significant relationship between cytokines and HbA1c levels in people with LTBI and DM (n=30) or pre-DM (n=30) has been previously reported.
11
Investigation of the quantitative IGRA results found that no indicators of severity of diabetes were related to level of TB antigen-nil. This was different to results presented from a Tanzanian study that found lower TB antigen specific interferon gamma release in patients with diabetes, regardless of their TB status. However, the patients with diabetes were all newly diagnosed and not yet on treatment. 30 The overall proportion of indeterminate results in our DM study (4.9%) was higher than the rate of indeterminate results observed in the younger age-and sex-matched groups (DM 3.6%; Control 1.4%), and in Indonesian children (3%). 31 The proportion of indeterminate results in adults is estimated to be between 4 and 6% although in studies of immunosuppressed people this can range from 3 to 27%. 17, 32 The proportion found in our study therefore appears to be acceptable. The increasing odds of an indeterminate result with HbA1c ≥10% (OR 3.22; 95% CI 1.36-7.61) suggests DM is associated with impaired T-cell responses.
To our knowledge, this is the first study to report LTBI prevalence using IGRA in patients with DM in Indonesia, and to have a comparison control group. It is a relatively large study with recruitment of patients both from a referral hospital and CHCs although it may not be representative of the DM population in Indonesia. The main limitation is that the study was crosssectional so we have no ability to provide a timeline for the acquisition of M. tuberculosis infection or to estimate the progression from LTBI to TB disease. There may have been some mis-classification due to issues related to the sensitivity and specificity of the IGRA test. The estimation of patients with a history of TB, and those on current TB treatment, was self-reported and confirmation of their diagnosis was not available. In the control group, their age and sex was not available and were imputed based on assumptions (Supplementary data). Finally, this study was focused on pulmonary TB and we may have missed some cases of sub-clinical extrapulmonary TB.
We have shown that LTBI is reasonably common in our study population of patients with DM, as is undiagnosed TB disease. DM patients should therefore be considered a potential high priority group for preventive therapy, however, it would be important to consider the age of the patients and the risk of adverse reactions and drug-drug interactions. 33 Noting the benefits of prophylactic treatment in HIV patients, further studies are needed to quantify the risks and benefits of such an approach in the growing group of people with LTBI and DM in TB-endemic settings.
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Supplementary data
Supplementary data are available at Transactions online (http://trstmh.oxfordjournals.org/).
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